Clinical and Laboratory Findings on the Differences Between H1N1 Influenza and Coronavirus Disease-2019 (COVID-19): Focusing on the Treatment Approach

In this study, therefore, we compared some clinical, demographic, and laboratory findings to determine the differences between H1N1 influenza and coronavirus disease-2019 (COVID-19) to suggest the appropriate drug therapeutic approaches. Subsequent to the inclusion of 4 available studies, which presented all the required data, the findings and results were compared, showing fever and cough as the most prevalent clinical indications of both H1N1 influenza and 2019-nCoV diseases. With respect to the laboratory findings, both 2019-nCoV and H1N1 patients showed leukopenia as the main laboratory findings. Taken together, since similar diagnostic methods are used for H1N1 and 2019-nCoV patients and they have the same clinical and laboratory features, it is safe to say that lopinavir/ritonavir and nucleoside analogues could be drug treatment options for patients suffering from 2019-nCoV. However, given the current urgent condition, the primary and main intervention procedure is controlling the infection so as to halt the dissemination of COVID-19. It is recommended, however, that the providers of public health care maintain a close watch on the situation, because the more information we obtain about this new virus and the ensuing epidemic, the faster we can react.
Source: Clinical Pulmonary Medicine - Category: Respiratory Medicine Tags: Critical Care/Respiratory Care Source Type: research